Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 218

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Computational pharmaceutics - A new paradigm of drug delivery

Wang, Wei, Ye, Zhuyifan, Gao, Hanlu, Ouyang, Defang·2021·Journal of Controlled Release

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2021.08.030

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 171

  1. Chong, 2007, New uses for old drugs, Nature, 448, 645, 10.1038/448645a · DOI · Paper page
  2. Beg, 2011, Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations, Curr. Drug Deliv., 8, 691, 10.2174/156720111797635504 · doi:10.2174/156720111797635504
  3. Park, 2015, Drug delivery of the future: Chasing the invisible gorilla, J. Control. Release, 240, 2
  4. Kinam, 2014, Controlled drug delivery systems: Past forward and future back, J. Control. Release, 190, 3, 10.1016/j.jconrel.2014.03.054 · DOI · Paper page
  5. Barratt, 2011, Takeru Higuchi, the man and the scientist, Int. J. Pharm., 418, 3, 10.1016/j.ijpharm.2011.05.019 · doi:10.1016/j.ijpharm.2011.05.019
  6. Clark, 2015, Medical aerosol inhalers: past, present, and future, Aerosol Sci. Technol., 22, 374, 10.1080/02786829408959755 · DOI
  7. Pastore, 2015, Transdermal patches: history, development and pharmacology, Br. J. Pharmacol., 172, 2179, 10.1111/bph.13059 · DOI · Paper page
  8. Yun, 2015, Controlled drug delivery: historical perspective for the next generation, J. Control. Release, 219, 2, 10.1016/j.jconrel.2015.10.005 · DOI · Paper page
  9. Miele, 2009, Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer, Int. J. Nanomedicine, 4, 99
  10. Park, 2019, The beginning of the end of the nanomedicine hype, J. Control. Release, 305, 221, 10.1016/j.jconrel.2019.05.044 · DOI · Paper page
  11. Nakamura, 2016, Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?, Bioconjug. Chem., 27, 2225, 10.1021/acs.bioconjchem.6b00437 · DOI · Paper page
  12. Rowe, 1998, Artificial intelligence in pharmaceutical product formulation: Knowledge-based and expert systems, Pharm. Sci. Technol. Today, 1, 153, 10.1016/S1461-5347(98)00042-X · doi:10.1016/s1461-5347(98)00042-x
  13. Yu, 2014, Understanding pharmaceutical quality by design, AAPS J., 16, 771, 10.1208/s12248-014-9598-3 · DOI · Paper page
  14. Yu, 2019, FDA's new pharmaceutical quality initiative: knowledge-aided assessment & structured applications, Int. J. Pharm. X, 1, 100010
  15. Zhao, 2019, Generating model integrated evidence for generic drug development and assessment, Clin. Pharmacol. Ther., 105, 338, 10.1002/cpt.1282 · DOI
  16. Marshall, 2019, Model-informed drug discovery and development: current industry good practice and regulatory expectations and future perspectives, CPT Pharmacometrics Syst. Pharmacol., 8, 87, 10.1002/psp4.12372 · DOI · Paper page
  17. Sato, 2017, Quantitative modeling and simulation in PMDA: a Japanese regulatory perspective, CPT Pharmacometrics Syst. Pharmacol., 6, 413, 10.1002/psp4.12203 · DOI
  18. 2009, 74(109), 27325
  19. Schuhmacher, 2020, The upside of being a digital pharma player, Drug Discov. Today, 10.1016/j.drudis.2020.06.002 · DOI
  20. Schuhmacher, 2019, The Art of Virtualizing Pharma R&D, Drug Discov. Today, 24, 2105, 10.1016/j.drudis.2019.07.004 · DOI
  21. Hussain, 1991, Application of neural computing in pharmaceutical product development, Pharm. Res., 8, 1248, 10.1023/A:1015843527138 · DOI
  22. Erb, 1993, Introduction to backpropagation neural network computation, Pharm. Res., 10, 165, 10.1023/A:1018966222807 · DOI · Paper page
  23. Rowe, 1998, Artificial intelligence in pharmaceutical product formulation: Neural computing and emerging technologies, Pharm. Sci. Technol. Today, 1, 200, 10.1016/S1461-5347(98)00055-8 · DOI
  24. Takayama, 1999, Artificial neural network as a novel method to optimize pharmaceutical formulations, Pharm. Res., 16, 1, 10.1023/A:1011986823850 · DOI
  25. Sun, 2003, Application of artificial neural networks in the design of controlled release drug delivery systems, Adv. Drug Deliv. Rev., 55, 1201, 10.1016/S0169-409X(03)00119-4 · DOI · Paper page
  26. Takayama, 2003, Neural network based optimization of drug formulations, Adv. Drug Deliv. Rev., 55, 1217, 10.1016/S0169-409X(03)00120-0 · DOI
  27. Ekins, 2006, Application of data mining approaches to drug delivery, Adv. Drug Deliv. Rev., 58, 1409, 10.1016/j.addr.2006.09.005 · DOI
  28. Colbourn, 2009, Novel approaches to neural and evolutionary computing in pharmaceutical formulation: Challenges and new possibilities, Future Med. Chem., 1, 713, 10.4155/fmc.09.57 · doi:10.4155/fmc.09.57
  29. Ibrić, 2012, Artificial neural networks in evaluation and optimization of modified release solid dosage forms, Pharmaceutics, 4, 531, 10.3390/pharmaceutics4040531 · DOI
  30. Dai, 2019, SeDeM expert system for directly compressed tablet formulation: A review and new perspectives, Powder Technol., 342, 517, 10.1016/j.powtec.2018.10.027 · doi:10.1016/j.powtec.2018.10.027
  31. Zhang, 2011, Design of an expert system for the development and formulation of push-pull osmotic pump tablets containing poorly water-soluble drugs, Int. J. Pharm., 410, 41, 10.1016/j.ijpharm.2011.03.013 · doi:10.1016/j.ijpharm.2011.03.013
  32. Hamman, 2018, Development of multiple-unit pellet system tablets by employing the SeDeM expert diagram system I: pellets with different sizes, Pharm. Dev. Technol., 23, 706, 10.1080/10837450.2017.1342657 · doi:10.1080/10837450.2017.1342657
  33. Hamman, 2019, Development of multiple-unit pellet system tablets by employing the SeDeM expert diagram system II: pellets containing different active pharmaceutical ingredients, Pharm. Dev. Technol., 24, 145, 10.1080/10837450.2018.1435691 · doi:10.1080/10837450.2018.1435691
  34. Aguilar-Díaz, 2012, Predicting orally disintegrating tablets formulations of ibuprophen tablets: an application of the new SeDeM-ODT expert system, Eur. J. Pharm. Biopharm., 80, 638, 10.1016/j.ejpb.2011.12.012 · doi:10.1016/j.ejpb.2011.12.012
  35. Wang, 2021, PharmDE: a new expert system for drug-excipient compatibility evaluation, Int. J. Pharm., 120962, 10.1016/j.ijpharm.2021.120962 · DOI
  36. Han, 2019, Predicting physical stability of solid dispersions by machine learning techniques, J. Control. Release, 311-312, 16, 10.1016/j.jconrel.2019.08.030 · DOI · Paper page
  37. Gao, 2021, An integrated computational methodology with data-driven machine learning, molecular modeling and PBPK modeling to accelerate solid dispersion formulation design, Eur. J. Pharm. Biopharm., 158, 336, 10.1016/j.ejpb.2020.12.001 · DOI
  38. Zhao, 2019, Predicting complexation performance between cyclodextrins and guest molecules by integrated machine learning and molecular modeling techniques, Acta Pharm. Sin. B, 9, 1241, 10.1016/j.apsb.2019.04.004 · DOI
  39. He, 2020, Can machine learning predict drug nanocrystals?, J. Control. Release, 322, 274, 10.1016/j.jconrel.2020.03.043 · DOI
  40. Gao, 2021, Integrated in silico formulation design of self-emulsifying drug delivery systems, Acta Pharm. Sin. B
  41. Ye, 2019, An integrated transfer learning and multitask learning approach for pharmacokinetic parameter prediction, Mol. Pharm., 16, 533, 10.1021/acs.molpharmaceut.8b00816 · DOI
  42. Ye, Z., et al., Interpretable Machine Learning Methods for In Vitro Pharmaceutical Formulation Development. 2021. 2(2): p. 195–207.DOI: doi:https://doi.org/10.1002/fft2.78. · DOI
  43. Tang, 2021, GANDA: A deep generative adversarial network conditionally generates intratumoral nanoparticles distribution pixels-to-pixels, J. Control. Release, 336, 336, 10.1016/j.jconrel.2021.06.039 · DOI
  44. Silva-Júnior, 2017, Quantum Mechanical (QM) Calculations Applied to ADMET Drug Prediction: A Review, Curr. Drug Metab., 18, 511, 10.2174/1389200218666170316094514 · doi:10.2174/1389200218666170316094514
  45. Sibambo, 2007, Elucidation of the physicomechanical and ab initio quantum energy transitions of a crosslinked PLGA scaffold, Biomaterials, 28, 3714, 10.1016/j.biomaterials.2007.04.045 · DOI
  46. Abramov, 2020, Guiding lead optimization for solubility improvement with physics-based modeling, Mol. Pharm., 10.1021/acs.molpharmaceut.9b01138 · doi:10.1021/acs.molpharmaceut.9b01138
  47. Klimeš, 2010, Chemical accuracy for the van der Waals density functional, J. Phys. Condens. Matter, 22(2)
  48. MacKerell, 1998, All-atom empirical potential for molecular modeling and dynamics studies of proteins, J. Phys. Chem. B, 102, 3586, 10.1021/jp973084f · DOI · Paper page
  49. Chan, 2018, Investigating the molecular dissolution process of binary solid dispersions by molecular dynamics simulations, Asian J. Pharmaceutical Sci., 13, 248
  50. Leuner, 2000, Improving drug solubility for oral delivery using solid dispersions, Eur. J. Pharm. Biopharm., 50, 47, 10.1016/S0939-6411(00)00076-X · DOI · Paper page
  51. Ouyang, 2012, Investigating the molecular structures of solid dispersions by the simulated annealing method, Chem. Phys. Lett., 554, 177, 10.1016/j.cplett.2012.10.056 · DOI
  52. Floresta, 2019, Supramolecular host-guest interactions of pseudoginsenoside F11 with β- and γ-cyclodextrin: Spectroscopic/spectrometric and computational studies, J. Mol. Struct., 1195, 387, 10.1016/j.molstruc.2019.05.134 · doi:10.1016/j.molstruc.2019.05.134
  53. Sun, 2018, Mechanism and structure studies of cinnamaldehyde/cyclodextrins inclusions by computer simulation and NMR technology, Carbohydr. Polym., 194, 294, 10.1016/j.carbpol.2018.04.055 · doi:10.1016/j.carbpol.2018.04.055
  54. Mokhtar, 2019, Atrazine and ametryne inclusion complexes with 2-hydroxypropyl-β/γ-cyclodextrin: Spectroscopic studies and molecular dynamics simulation, J. Mol. Struct., 1179, 161, 10.1016/j.molstruc.2018.11.002 · DOI
  55. Mokhtar, 2018, Experimental and molecular modeling investigations of inclusion complexes of imazapyr with 2-hydroxypropyl(β/γ) cyclodextrin, J. Mol. Liq., 262, 504, 10.1016/j.molliq.2018.04.088 · doi:10.1016/j.molliq.2018.04.088
  56. Yasuda, 2019, Molecular dynamics of polyrotaxane in solution investigated by Quasi-elastic neutron scattering and molecular dynamics simulation: sliding motion of rings on polymer, J. Am. Chem. Soc., 141, 9655, 10.1021/jacs.9b03792 · doi:10.1021/jacs.9b03792
  57. Medarević, 2015, Influence of hydrophilic polymers on the complexation of carbamazepine with hydroxypropyl-β-cyclodextrin, Eur. J. Pharm. Sci., 78, 273, 10.1016/j.ejps.2015.08.001 · DOI
  58. Alvira, 2019, Molecular simulation of the separation of isoleucine enantiomers by β-Cyclodextrin, Molecules, 24, 1021, 10.3390/molecules24061021 · doi:10.3390/molecules24061021
  59. Alvira, 2017, Influence of solvent polarity on the separation of leucine enantiomers by β-cyclodextrin: a molecular mechanics and dynamics simulation, Tetrahedron Asymmetry, 28, 1414, 10.1016/j.tetasy.2017.09.020 · doi:10.1016/j.tetasy.2017.09.020
  60. Zhao, 2018, Computer-aided formulation design for a highly soluble lutein–cyclodextrin multiple-component delivery system, Mol. Pharm., 15, 1664, 10.1021/acs.molpharmaceut.8b00056 · doi:10.1021/acs.molpharmaceut.8b00056
  61. Gao, 2021, Integrated computer-aided formulation design: a case study of andrographolide/cyclodextrin ternary formulation, Asian J. Pharmaceutical Sci.
  62. Ntountaniotis, 2019, Host–Guest interactions between candesartan and its prodrug candesartan cilexetil in complex with 2-Hydroxypropyl-β-cyclodextrin: on the biological potency for angiotensin II antagonism, Mol. Pharm., 16, 1255, 10.1021/acs.molpharmaceut.8b01212 · doi:10.1021/acs.molpharmaceut.8b01212
  63. Ouyang, 2010, Structure, dynamics, and energetics of siRNA−Cationic vector complexation: a molecular dynamics study, J. Phys. Chem. B, 114, 9220, 10.1021/jp911906e · DOI
  64. Ouyang, 2010, Structure and dynamics of multiple cationic vectors−siRNA complexation by all-atomic molecular dynamics simulations, J. Phys. Chem. B, 114, 9231, 10.1021/jp911913c · doi:10.1021/jp911913c
  65. Sun, 2013, A molecular dynamics simulation study on the effect of lipid substitution on polyethylenimine mediated siRNA complexation, Biomaterials, 34, 2822, 10.1016/j.biomaterials.2013.01.011 · doi:10.1016/j.biomaterials.2013.01.011
  66. Monpara, 2019, Cationic cholesterol derivative efficiently delivers the genes: in silico and in vitro studies, Drug Deliv. Transl. Res., 9, 106, 10.1007/s13346-018-0571-z · doi:10.1007/s13346-018-0571-z
  67. Lakshminarayanan, 2013, Efficient dendrimer–DNA complexation and gene delivery vector properties of nitrogen-core poly(propyl ether imine) dendrimer in mammalian cells, Bioconjug. Chem., 24, 1612, 10.1021/bc400247w · DOI
  68. Abel, 2012, Molecular dynamics simulations of a characteristic DPC micelle in water, J. Chem. Theory Comput., 8, 4610, 10.1021/ct3003207 · DOI
  69. Faramarzi, 2017, Molecular dynamics simulations as a tool for accurate determination of surfactant micelle properties, Langmuir, 33, 9934, 10.1021/acs.langmuir.7b02666 · DOI
  70. He, 2017, Simulation study of interaction mechanism between peptide and asymmetric membrane, Mol. Simul., 43, 34, 10.1080/08927022.2016.1228105 · doi:10.1080/08927022.2016.1228105
  71. Kmiecik, 2016, Coarse-grained protein models and their applications, Chem. Rev., 116, 7898, 10.1021/acs.chemrev.6b00163 · DOI · Paper page
  72. Tabujew, 2019, Tackling the limitations of copolymeric small interfering RNA delivery agents by a combined experimental–computational approach, Biomacromolecules, 20, 4389, 10.1021/acs.biomac.9b01061 · DOI
  73. Bruininks, 2020, A molecular view on the escape of lipoplexed DNA from the endosome, eLife, 9, 10.7554/eLife.52012 · DOI
  74. Wang, 1999, General solution for diffusion-controlled dissolution of spherical particles. 1. Theory, J. Pharm. Sci., 88, 731, 10.1021/js980236p · DOI · Paper page
  75. Kieckhefen, 2020, Possibilities and limits of computational fluid dynamics-discrete element method simulations in process engineering: a review of recent advancements and future trends, Annu. Rev. Chem. Biomol. Eng., 11, 397, 10.1146/annurev-chembioeng-110519-075414 · doi:10.1146/annurev-chembioeng-110519-075414
  76. Yeom, 2019, Application of the discrete element method for manufacturing process simulation in the pharmaceutical industry, Pharmaceutics, 11, 10.3390/pharmaceutics11080414 · DOI · Paper page
  77. Noyes, 1897, The Rate of Solution of Solid Substances in Their Own Solutions, J. Am. Chem. Soc., 19, 930, 10.1021/ja02086a003 · DOI · Paper page
  78. Peppas, 2014, Mathematical models in drug delivery: how modeling has shaped the way we design new drug delivery systems, J. Control. Release, 190, 75, 10.1016/j.jconrel.2014.06.041 · DOI · Paper page
  79. Siepmann, 2008, Mathematical modeling of drug delivery, Int. J. Pharm., 364, 328, 10.1016/j.ijpharm.2008.09.004 · DOI · Paper page
  80. Mircioiu, 2019, Mathematical modeling of release kinetics from supramolecular drug delivery systems, Pharmaceutics, 11, 10.3390/pharmaceutics11030140 · DOI · Paper page
  81. Grassi, 2014, Application of mathematical modeling in sustained release delivery systems, Expert. Opin. Drug Deliv., 11, 1299, 10.1517/17425247.2014.924497 · doi:10.1517/17425247.2014.924497
  82. Higuchi, 1961, Rate of release of medicaments from ointment bases containing drugs in suspension, J. Pharm. Sci., 50, 874, 10.1002/jps.2600501018 · DOI · Paper page
  83. Korsmeyer, R.W., Lustig, S.R., and Peppas, N.A., Solute and penetrant diffusion in swellable polymers. II. Verification of theoretical models. J. Polym. Sci. Polym. Phys. 24: p. 409–434. · DOI · Paper page
  84. Narasimhan, 1997, Molecular analysis of drug delivery systems controlled by dissolution of the polymer carrier, J. Pharm. Sci., 86, 297, 10.1021/js960372z · DOI · Paper page
  85. Siepmann, 2000, Hydrophilic matrices for controlled drug delivery: an improved mathematical model to predict the resulting drug release kinetics (the “sequential layer” model), Pharm. Res., 17, 1290, 10.1023/A:1026455822595 · DOI · Paper page
  86. Siepmann, 2002, A new mathematical model quantifying drug release from bioerodible microparticles using Monte Carlo simulations, Pharm. Res., 19, 1885, 10.1023/A:1021457911533 · DOI · Paper page
  87. Tzur-Balter, 2013, Mathematical modeling of drug release from nanostructured porous Si: combining carrier erosion and hindered drug diffusion for predicting release kinetics, Acta Biomater., 9, 8346, 10.1016/j.actbio.2013.06.007 · DOI
  88. Peppas, 1985, Analysis of Fickian and non-Fickian drug release from polymers, Pharm. Acta Helv., 60, 110
  89. Cooney, 1972, Effect of geometry on the dissolution of pharmaceutical tablets and other solids: Surface detachment kinetics controlling, AICHE J., 18, 446, 10.1002/aic.690180234 · DOI
  90. Delplace, 2019, Controlled release strategy designed for intravitreal protein delivery to the retina, J. Control. Release, 293, 10, 10.1016/j.jconrel.2018.11.012 · DOI
  91. Vulic, 2015, Mathematical model accurately predicts protein release from an affinity-based delivery system, J. Control. Release, 197, 69, 10.1016/j.jconrel.2014.10.032 · DOI
  92. Haghiralsadat, 2018, A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery, Artif. Cells Nanomed. Biotechnol., 46, 169, 10.1080/21691401.2017.1304403 · DOI
  93. Jakubiak, 2016, Development of a unified dissolution and precipitation model and its use for the prediction of oral drug absorption, Mol. Pharm., 13, 586, 10.1021/acs.molpharmaceut.5b00808 · DOI
  94. Bennema, 1977, Crystal growth from solution: development in computer simulation, J. Cryst. Growth, 42, 201, 10.1016/0022-0248(77)90196-8 · doi:10.1016/0022-0248(77)90196-8
  95. Baldan, 2002, Review Progress in Ostwald ripening theories and their applications to nickel-base superalloys Part I: Ostwald ripening theories, J. Mater. Sci., 37, 2171, 10.1023/A:1015388912729 · DOI · Paper page
  96. Penn, 1998, Imperfect oriented attachment: dislocation generation in defect-free nanocrystals, Science, 281, 969, 10.1126/science.281.5379.969 · DOI · Paper page
  97. Zhang, 2010, Progress of nanocrystalline growth kinetics based on oriented attachment, Nanoscale, 2, 18, 10.1039/B9NR00047J · DOI · Paper page
  98. Weiss, 1986, Overview of theoretical models for reaction rates, J. Stat. Phys., 42, 3, 10.1007/BF01010838 · doi:10.1007/bf01010838
  99. Ma, 2008, Crystal growth rate dispersion modeling using morphological population balance, AICHE J., 54, 2321, 10.1002/aic.11549 · doi:10.1002/aic.11549
  100. Rachah, 2016, A mathematical model for continuous crystallization, Math. Methods Appl. Sci., 39, 1101, 10.1002/mma.3553 · doi:10.1002/mma.3553
  101. Vetter, 2013, Modeling nucleation, growth, and Ostwald ripening in crystallization processes: a comparison between population balance and kinetic rate equation, Cryst. Growth Des., 13, 4890, 10.1021/cg4010714 · DOI
  102. Ma, 2018, Combining morphological population balances with face-specific growth kinetics data to model and predict the crystallization processes for ibuprofen, Ind. Eng. Chem. Res., 57, 16379, 10.1021/acs.iecr.8b02140 · DOI
  103. Gao, 2021, An integrated computational methodology with data-driven machine learning, molecular modeling and PBPK modeling to accelerate solid dispersion formulation design, Eur. J. Pharm. Biopharm., 158, 336, 10.1016/j.ejpb.2020.12.001 · DOI
  104. Grassi, 2000, Drug release from an ensemble of swellable crosslinked polymer particles, J. Control. Release, 68, 97, 10.1016/S0168-3659(00)00241-8 · DOI
  105. Andersen, 2019, A practical guide to surface kinetic Monte Carlo simulations, Front. Chem., 7, 10.3389/fchem.2019.00202 · DOI · Paper page
  106. Kremer, 2006, Process simulation in the pharmaceutical industry: a review of some basic physical models, J. Pharm. Sci., 95, 517, 10.1002/jps.20583 · DOI
  107. Jang, 2020, Model-based scale-up methodologies for pharmaceutical granulation, Pharmaceutics, 12, 10.3390/pharmaceutics12050453 · doi:10.3390/pharmaceutics12050453
  108. Khorasani, 2016, Process optimization of dry granulation based tableting line: Extracting physical material characteristics from granules, ribbons and tablets using near-IR (NIR) spectroscopic measurement, Powder Technol., 300, 120, 10.1016/j.powtec.2016.03.004 · doi:10.1016/j.powtec.2016.03.004
  109. Narang, 2017, Application of in-line focused beam reflectance measurement to brivanib alaninate wet granulation process to enable scale-up and attribute-based monitoring and control strategies, J. Pharm. Sci., 106, 224, 10.1016/j.xphs.2016.08.025 · doi:10.1016/j.xphs.2016.08.025
  110. Nagy, 2017, In-line Raman spectroscopic monitoring and feedback control of a continuous twin-screw pharmaceutical powder blending and tableting process, Int. J. Pharm., 530, 21, 10.1016/j.ijpharm.2017.07.041 · DOI
  111. Saleemi, 2012, Enhancing crystalline properties of a cardiovascular active pharmaceutical ingredient using a process analytical technology based crystallization feedback control strategy, Int. J. Pharm., 430, 56, 10.1016/j.ijpharm.2012.03.029 · DOI
  112. Kim, 2011, Application of internal seeding and temperature cycling for reduction of liquid inclusion in the crystallization of RDX, Org. Process. Res. Dev., 15, 602, 10.1021/op100334y · doi:10.1021/op100334y
  113. Vargas, 2018, Process analytical technology in continuous manufacturing of a commercial pharmaceutical product, Int. J. Pharm., 538, 167, 10.1016/j.ijpharm.2018.01.003 · DOI
  114. Babnik, 2020, A review of computational fluid dynamics (CFD) simulations of mixing in the pharmaceutical industry, Biomed. J. Sci. Tech. Res., 3, 20732
  115. Ding, 1990, A bubbling fluidization model using kinetic theory of granular flow, AICHE J., 36, 523, 10.1002/aic.690360404 · DOI · Paper page
  116. Mortier, 2011, Mechanistic modelling of fluidized bed drying processes of wet porous granules: a review, Eur. J. Pharm. Biopharm., 79, 205, 10.1016/j.ejpb.2011.05.013 · DOI
  117. Jamaleddine, 2010, Application of computational fluid dynamics for simulation of drying processes: a review, Dry. Technol., 28, 120, 10.1080/07373930903517458 · DOI · Paper page
  118. Alexeenko, 2009, Computational analysis of fluid dynamics in pharmaceutical freeze-drying, J. Pharm. Sci., 98, 3483, 10.1002/jps.21862 · DOI
  119. Barresi, 2018, Use of computational fluid dynamics for improving freeze-dryers design and process understanding. Part 1: modelling the lyophilisation chamber, Eur. J. Pharm. Biopharm., 129, 30, 10.1016/j.ejpb.2018.05.008 · doi:10.1016/j.ejpb.2018.05.008
  120. Marchisio, 2018, Use of computational fluid dynamics for improving freeze-dryers design and process understanding. Part 2: Condenser duct and valve modelling, Eur. J. Pharm. Biopharm., 129, 45, 10.1016/j.ejpb.2018.05.003 · doi:10.1016/j.ejpb.2018.05.003
  121. Zhang, 2002, Aerosol transport and deposition in a triple bifurcation bronchial airway model with local tumors, Inhal. Toxicol., 14, 1111, 10.1080/08958370290084809 · doi:10.1080/08958370290084809
  122. Mitsakou, 2005, Eulerian modelling of lung deposition with sectional representation of aerosol dynamics, J. Aerosol Sci., 36, 75, 10.1016/j.jaerosci.2004.08.008 · DOI
  123. Ruzycki, 2013, The use of computational fluid dynamics in inhaler design, Expert Opin. Drug Deliv., 10, 307, 10.1517/17425247.2013.753053 · doi:10.1517/17425247.2013.753053
  124. Das, 2018, Targeting inhaled aerosol delivery to upper airways in children: Insight from computational fluid dynamics (CFD), PLoS One, 13, 10.1371/journal.pone.0207711 · DOI
  125. Kannan, 2017, Pharmaceutical aerosols deposition patterns from a Dry Powder Inhaler: Euler Lagrangian prediction and validation, Med. Eng. Phys., 42, 35, 10.1016/j.medengphy.2016.11.007 · doi:10.1016/j.medengphy.2016.11.007
  126. Newman, 2000, Scintigraphic comparison of budesonide deposition from two dry powder inhalers, Eur. Respir. J., 16, 178, 10.1034/j.1399-3003.2000.16a29.x · doi:10.1034/j.1399-3003.2000.16a29.x
  127. Tian, 2015, Validating CFD predictions of pharmaceutical aerosol deposition with in vivo data, Pharm. Res., 32, 3170, 10.1007/s11095-015-1695-1 · DOI
  128. Zhu, 2007, Discrete particle simulation of particulate systems: theoretical developments, Chem. Eng. Sci., 62, 3378, 10.1016/j.ces.2006.12.089 · DOI · Paper page
  129. Zhang, 2020, Discrete element analysis of normal elastic impact of wet particles, Powder Technol., 362, 628, 10.1016/j.powtec.2019.12.021 · doi:10.1016/j.powtec.2019.12.021
  130. Liu, 2020, Migration and agglomeration of adhesive microparticle suspensions in a pressure-driven duct flow, AICHE J., 66, 10.1002/aic.16974 · doi:10.1002/aic.16974
  131. Capozzi, 2019, A multi-scale computational framework for modeling the freeze-drying of microparticles in packed-beds, Powder Technol., 343, 834, 10.1016/j.powtec.2018.11.067 · doi:10.1016/j.powtec.2018.11.067
  132. Jones, 2013, Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development, CPT Pharmacometrics Syst. Pharmacol., 2, 1, 10.1038/psp.2013.41 · DOI · Paper page
  133. Teorell, 1937, Kinetics of distribution of substances administered to the body, I: the extravascular modes of administration, Arch. Int. Pharmacodyn. Therapie, 57, 205
  134. Yu, 1996, Compartmental transit and dispersion model analysis of small intestinal transit flow in humans, Int. J. Pharm., 140, 111, 10.1016/0378-5173(96)04592-9 · DOI · Paper page
  135. Thelen, 2012, Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: Extension to describe performance of solid dosage forms, J. Pharm. Sci., 101, 1267, 10.1002/jps.22825 · DOI
  136. Winiwarter, 1998, Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach, J. Med. Chem., 41, 4939, 10.1021/jm9810102 · DOI · Paper page
  137. Ghate, 2019, Physiologically based pharmacokinetic (PBPK) modelling for in vitro-in vivo extrapolation: emphasis on the use of dissolution data, Dissol. Technol., 26, 18, 10.14227/DT260319P18 · DOI
  138. Kostewicz, 2014, PBPK models for the prediction of in vivo performance of oral dosage forms, Eur. J. Pharm. Sci., 57, 300, 10.1016/j.ejps.2013.09.008 · DOI · Paper page
  139. Shah, 2013, Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process, J. Pharm. Sci., 102, 967, 10.1002/jps.23425 · DOI · Paper page
  140. Kawabata, 2011, Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications, Int. J. Pharm., 420, 1, 10.1016/j.ijpharm.2011.08.032 · DOI · Paper page
  141. Thakore, 2019, Assessment of biopharmaceutical performance of supersaturating formulations of carbamazepine in rats using physiologically based pharmacokinetic modeling, AAPS PharmSciTech, 20, 10.1208/s12249-019-1386-z · doi:10.1208/s12249-019-1386-z
  142. Purohit, 2018, Investigating the impact of drug crystallinity in amorphous tacrolimus capsules on pharmacokinetics and bioequivalence using discriminatory in vitro dissolution testing and physiologically based pharmacokinetic modeling and simulation, J. Pharm. Sci., 107, 1330, 10.1016/j.xphs.2017.12.024 · doi:10.1016/j.xphs.2017.12.024
  143. Dahan, 2010, The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone, J. Pharm. Sci., 99, 2739, 10.1002/jps.22033 · DOI · Paper page
  144. Sun, 2018, The solubility-permeability trade-off of progesterone with cyclodextrins under physiological conditions: experimental observations and computer simulations, J. Pharm. Sci., 107, 488, 10.1016/j.xphs.2017.09.032 · doi:10.1016/j.xphs.2017.09.032
  145. Wang, 2021, Prediction of free drug absorption in cyclodextrin formulation by a modified physiologically based pharmacokinetic model and phase solubility 3-d surface graph, Pharm. Res., 10.1007/s11095-021-03071-3 · DOI
  146. Williams, 2013, Strategies to address low drug solubility in discovery and development, Pharmacol. Rev., 65, 315, 10.1124/pr.112.005660 · DOI · Paper page
  147. Rasenack, 2002, Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs, Pharm. Res., 19, 1894, 10.1023/A:1021410028371 · DOI · Paper page
  148. Li, 2019, Justification of biowaiver and dissolution rate specifications for piroxicam immediate release products based on physiologically based pharmacokinetic modeling: an in-depth analysis, Mol. Pharm., 16, 3780, 10.1021/acs.molpharmaceut.9b00350 · DOI
  149. Zhang, 2014, Application of physiologically based absorption modeling to formulation development of a low solubility, low permeability weak base: Mechanistic investigation of food effect, AAPS PharmSciTech, 15, 400, 10.1208/s12249-014-0075-1 · DOI
  150. Litou, 2019, Combining biorelevant in vitro and in silico tools to simulate and better understand the in vivo performance of a nano-sized formulation of aprepitant in the fasted and fed states, Eur. J. Pharm. Sci., 138, 105031, 10.1016/j.ejps.2019.105031 · DOI
  151. Shono, 2010, Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans, Eur. J. Pharm. Biopharm., 76, 95, 10.1016/j.ejpb.2010.05.009 · DOI
  152. Parrott, 2014, Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin, AAPS J., 16, 1077, 10.1208/s12248-014-9639-y · DOI
  153. O'Shea, 2015, Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: in vitro, in vivo and in silico assessments, Eur. J. Pharm. Biopharm., 96, 207, 10.1016/j.ejpb.2015.07.014 · DOI
  154. Emami Riedmaier, 2018, Mechanistic physiologically based pharmacokinetic modeling of the dissolution and food effect of a biopharmaceutics classification system IV compound—The Venetoclax story, J. Pharm. Sci., 107, 495, 10.1016/j.xphs.2017.09.027 · DOI
  155. Kambayashi, 2019, PBPK modeling coupled with biorelevant dissolution to forecast the oral performance of amorphous solid dispersion formulations, Eur. J. Pharm. Sci., 135, 83, 10.1016/j.ejps.2019.05.013 · DOI
  156. Hansmann, 2018, An in silico approach to determine challenges in the bioavailability of ciprofloxacin, a poorly soluble weak base with borderline solubility and permeability characteristics, Eur. J. Pharm. Biopharm., 122, 186, 10.1016/j.ejpb.2017.10.019 · DOI
  157. Xia, 2013, Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compound, AAPS PharmSciTech, 14, 1255, 10.1208/s12249-013-0018-2 · DOI
  158. Dong, 2015, Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112, Int. J. Nanomedicine, 10, 2521
  159. Yuan, 2019, Physiologically based pharmacokinetic modeling of nanoparticles, J. Pharm. Sci., 108, 58, 10.1016/j.xphs.2018.10.037 · DOI · Paper page
  160. Boger, 2019, Physiologically based pharmacokinetic/pharmacodynamic modeling accurately predicts the better bronchodilatory effect of inhaled versus oral salbutamol dosage forms, J. Aerosol. Med. Pulm Drug Deliv., 32, 1, 10.1089/jamp.2017.1436 · DOI
  161. Chen, 2016, In silico modelling of transdermal and systemic kinetics of topically applied solutes: model development and initial validation for transdermal nicotine, Pharm. Res., 33, 1602, 10.1007/s11095-016-1900-x · doi:10.1007/s11095-016-1900-x
  162. Le Merdy, 2019, Application of mechanistic ocular absorption modeling and simulation to understand the impact of formulation properties on ophthalmic bioavailability in rabbits: a case study using dexamethasone suspension, AAPS J., 21, 10.1208/s12248-019-0334-x · doi:10.1208/s12248-019-0334-x
  163. Continuous Symposium
  164. Steinwandter, 2019, Data science tools and applications on the way to Pharma 4.0, Drug Discov. Today, 24, 1795, 10.1016/j.drudis.2019.06.005 · DOI
  165. Afantitis, 2020, NanoSolveIT Project: Driving nanoinformatics research to develop innovative and integrated tools for in silico nanosafety assessment, Comput. Struct. Biotechnol. J., 18, 583, 10.1016/j.csbj.2020.02.023 · DOI
  166. Lu, 2021, Deep learning prediction of patient response time course from early data via neural-pharmacokinetic/pharmacodynamic modelling, Nat. Mach. Intell., 10.1038/s42256-021-00357-4 · DOI
  167. Noé, 2020, Machine learning for molecular simulation, Annu. Rev. Phys. Chem., 71, 361, 10.1146/annurev-physchem-042018-052331 · DOI · Paper page
  168. Chiang, 2017, Big data analytics in chemical engineering, Annu. Rev. Chem. Biomol. Eng., 8, 63, 10.1146/annurev-chembioeng-060816-101555 · DOI · Paper page
  169. David, 2001, Productivity growth prospects and the new economy in historical perspective, EIB Papers, 6, 41
  170. David, 1990, The dynamo and the computer an historical perspective on the modern productivity paradox, Am. Econ. Rev., 80, 355
  171. Temin, 2008, Private borrowing during the financial revolution: hoare's bank and its customers, 1702-24, Econ. Hist. Riv., 62, 541, 10.1111/j.1468-0289.2007.00420.x · DOI

Cited by

See all 218

Metadata

Authors
Wang, W., Ye, Z., Gao, H., & Ouyang, D.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2021-10
Volume
338
Pages
119-136
ISSN
0168-3659 (ISSN-L)
OpenAlex
W3195421105
Cited by
218
References
14
FWCI
16.00
Type
journal article
Language
en
Open access
closed
Funders
Universidade de Macau (MYRG2019-00041-ICMS)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Computational pharmaceutics - A new paradigm of drug delivery. https://app.cochat.ai/papers/10.1016/j.jconrel.2021.08.030
The paper
Wang, W., Ye, Z., Gao, H., & Ouyang, D. (2021). Computational pharmaceutics - A new paradigm of drug delivery. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2021.08.030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.